Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ablynx : posts strong data on key drug, looks set for approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 10:40am CET

The drug, caplacizumab, is a treatment for the rare condition acquired thrombotic thrombocytopenic purpura (aTTP) and the data revealed a 74% reduction in aTTP-related death, recurrence of aTTP or at least one major thromboembolic event during treatment with its drug.

Additionally, the proportion of individuals that experienced recurrence of aTTP during the study was found 67% lower compared to those receiving placebo treatment.

In a further bonus to the drug, the safety profile was found to be extremely strong, with no major differences found between the drug and placebo treatment. The exception being a higher level of bleed-related adverse events, 66.2% against 49.3% in placebo though they were noted to be mild or moderate in severity.

Dr Edwin Moses, CEO of Ablynx, commented: I am delighted by this outcome as it reinforces all our beliefs in the potential for caplacizumab to change the lives of patients affected by aTTP. This is a very important milestone for the company as it further validates our Nanobody platform and demonstrates our ability to discover and develop medicines that make a real difference for society. These results strengthen our resolve to obtain marketing approval as quickly as possible so that caplacizumab rapidly becomes available to patients suffering from this severe disease for which there is currently no approved drug available.

Ablynx has already applied for marketing authorisation the EMA and plans to file with the FDA in 2018. One of the major successes for the company is that the Belgium-based biotech has taken the treatment all the way through to Phase 3 by itself and now looks set to secure the potential peak sales of $400 million exclusively. It has already announced that it plans to market the drug with its own sales force.

European biotechs have, so far, lagged behind their counterparts across the Atlantic but this success will go some way to suggesting that it is possible within Europe to develop a company able to take treatments all the way through developmental stage to potential marketing authorisation.

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
02/16ABLYNX : 16/02/2018 ablynx announces option exercise by sanofi for two additiona..
PU
02/16ABLYNX : Announces option exercise by sanofi for two additional multi-specific n..
GL
02/15ABLYNX : 15/02/2018 publication in accordance with article 14 of the belgian law..
PU
02/15ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
02/15ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
02/12Novo Nordisk Does Not Intend to Make a Revised Proposal for Ablynx
AQ
02/12ABLYNX : 12/02/2018 publication in accordance with article 14 of the belgian law..
PU
02/12ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
02/12ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
02/08Cardio/diabetes sales drag down Sanofi earnings
AQ
More news
News from SeekingAlpha
01/30YOUR DAILY PHARMA SCOOP : Sanofi To Acquire Ablynx, PTC Therapeutics Announces D.. 
01/22ABLYNX : Novo Offer Undervalues The Company 
01/20YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O.. 
01/17NOVO NORDISK : Don't Spoil The Ablynx Acquisition 
01/09YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici.. 
Financials (€)
Sales 2017 55,5 M
EBIT 2017 -51,2 M
Net income 2017 -70,5 M
Finance 2017 156 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 56,5x
EV / Sales 2018 56,0x
Capitalization 3 291 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 44,4 €
Spread / Average Target 1,3%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert K. Zeldin Chief Medical Officer
Robert Freisen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX111.00%4 116
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227